CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for LungLife AI Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

LungLife AI Inc
2545 W. Hillcrest Drive, Suite 140
Phone: (805) 409-9868p:805 409-9868 THOUSAND OAKS, CA  91320  United States Ticker: LLAILLAI
Business Summary
LungLife AI, Inc. is a developer of clinical diagnostic solutions for lung cancer. The Company is engaged in the development and commercialization of its lung cancer early detection test. The Company’s diagnostic, the LungLB test, is used as a tool to provide clinicians with additional information to help in the decision-making process for people with indeterminate lung nodules following a CT scan. The LungLB is a blood-based liquid biopsy assay that uses fluorescence in situ hybridization (FISH) and image analysis to identify circulating genetically abnormal cells (CGAC), which include circulating tumor cells (CTCs). The technique incorporates an artificial intelligence (AI)-derived image analysis strategy to identify unique cell populations reflective of the disease state under interrogation.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2835 In vitro and in vivo diagnostic substances
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board GordonDavis 66 7/8/2021 7/8/2021
Chief Executive Officer, Executive Director Paul C.Pagano 39 5/15/2020 5/15/2020
Chief Financial Officer, Executive Director, Company Secretary David M.Anderson 60 7/8/2021 7/8/2021
Senior Independent Non-Executive Director Andrew N.Boteler 7/8/2021 7/8/2021
Non-Executive Director Sara J.Barrington 55 7/8/2021 5/15/2020

General Information
Number of Employees: 15 (As of 12/31/2023)
Outstanding Shares: 30,658,603 (As of 6/30/2024)
Stock Exchange: LON
Fax Number: (805) 855-2003


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025